

Minutes

## Drug Utilization Review Board Meeting

DATE: March 14, 2024



**Meeting Purpose:** Quarterly Drug Utilization Board Meeting  
Meeting opened at 6:00 p.m. by Timothy Fensky, RPh.

The meeting was conducted under Massachusetts Public Meeting Law requirements.

**Attendance:** Mehmet Furkan Burbak, MD; Melissa Coyle, PharmD; Timothy Fensky, RPh; Colleen Labelle, MSN, RN-BC, CARN; Lori Lewicki, RPh; Sarah M McGee, MD; Laura Spring, MD; Karen Ryle, MS, RPh; Christy Stine, MD, PhD

**Absent:** Rebekah Rice, RPh, CDCES

### Agenda Items:

- Welcome and Introductory Remarks
- Guest Speakers
- Minutes
- Annual Pipeline Continuing Education Program
- Pediatric Behavioral Health Medication Initiative Quality Assurance Analysis
- MHDL Update
- DUR Operational Update
- MassHealth Update
- Open Forum

Agenda Item	Discussion	Conclusions/Follow Up
Guest Speakers	<ul style="list-style-type: none"><li>• Daniel Bassoff, Medical Knowledge Care Team at Sarepta Therapeutics, spoke on Elevidys.</li><li>• Jennifer Handt, parent, spoke on Elevidys.</li><li>• Brian Denger, parent and advocate at Parent Project Muscular Dystrophies, spoke on Elevidys.</li></ul>	<b><u>Follow Up</u></b> Informational/Advisory

Agenda Item	Discussion	Conclusions/Follow-up
Minutes	Motion to approve the minutes for December 2023 was made by Christy Stine, MD, PhD and seconded by Timothy Fensky, RPh.	<b><u>Follow-up</u></b> Minutes are approved.

Agenda Item	Discussion	Conclusions/Follow-up
Annual Pipeline Continuing Education Program	<b><u>Annual Pipeline Continuing Education by Dr. Collin Jerrard and Dr. Anhar Eldesouky</u></b> The Pipeline Updated provided an overview of clinical and/or regulatory updates regarding select pharmaceutical pipeline agents in late-stage development.	<b><u>Follow-up</u></b> Informational/Advisory
Action	Discussion <ul style="list-style-type: none"> <li>• Described recent trends in the FDA approval process</li> <li>• Compared and contrasted the emerging pipeline agents with current available therapeutic options</li> <li>• Summarized biosimilar product availability of reference agents over the coming year</li> </ul> Conclusions <ul style="list-style-type: none"> <li>• Immuno-oncology drugs continued to lead the pack for pipeline drug development.</li> <li>• Cell and gene therapy approvals continued to accelerate as the number of clinical trials trend upward.</li> <li>• Biosimilar adoption has been slow, due to numerous factors, such as the COVID-19 pandemic and provider/patient familiarity with reference products.</li> </ul>	<b><u>Conclusion</u></b> The board reviewed and accepted the presentation.

Agenda Item	Discussion	Conclusions/Follow-up
<b>Pediatric Behavioral Health Medication Initiative Quality Assurance Analysis</b>	<p><b><u>Pediatric Behavioral Health Medication Initiative Quality Assurance Analysis by Dr. Ashley Chiara</u></b></p> <p>This overview was an evaluation of current medical literature and provided a brief overview of new guideline recommendations in this disease state.</p>	<p><b><u>Follow-up</u></b> Informational/Advisory</p>
Action	<p>Discussion</p> <ul style="list-style-type: none"> <li>Reviewed the background of PBHMI, existing management, and Therapeutic Class Management (TCM) workgroup involvement</li> <li>Discussed recent quality management improvement (QI) and quality assurance (QA) efforts</li> <li>Reviewed the annual pediatric behavioral medication utilization data</li> <li>Outlined the recommended updates and changes to PBHMI restrictions and prior authorization (PA) criteria</li> </ul> <p>Recommendations</p> <ul style="list-style-type: none"> <li>Update antipsychotic age PA criteria</li> <li>Update interclass polypharmacy PA criteria</li> <li>Update specialist PA criteria</li> </ul>	<p><b><u>Conclusion</u></b> The board reviewed and accepted the presentation.</p>

Agenda Item	Discussion	Conclusions/Follow-up
<b>MassHealth Drug List (MHDL) Update</b>	<p><b><u>MHDL Update by Dr. Bon Van</u></b></p> <p>MHDL overview included new additions, changes in PA status, and related attachment updates to be implemented with a recent publication rollout.</p>	<p><b><u>Follow-up</u></b> Informational/Advisory</p>

Agenda Item	Discussion	Conclusions/Follow-up
Action	<p>Discussion</p> <ul style="list-style-type: none"> <li>• There was one addition to the MHDL Drug list effective April 1, 2024.</li> <li>• As of April 1, 2024, there were four agents added to the MassHealth Supplemental Rebate/Preferred Drug List, as well as additional changes to the MassHealth Acute Hospital Carve-Out Drugs List.</li> <li>• There were 17 additions to PA status to the MHDL Drug list effective May 6, 2024. Sixteen will require PA while one will not.</li> <li>• There were several changes to Coverage Status for Pharmacy Billing, Brand Name Preferred Over Generic List; 90-day Initiative; Over the Counter Drug List; Quick Reference Guide; Pharmacy Covered Professional Services List; and Preferred Non-Drug Products Listing</li> </ul>	<p><b><u>Conclusion</u></b> The board reviewed and accepted the presentation.</p>

Agenda Item	Discussion	Conclusions/Follow-up
<b>DUR Operational Update</b>	<p><b><u>DUR Operational Update by Dr. Patricia Leto</u></b> DUR operational overview included statistics associated with PA review and PA response, and call center metrics.</p>	<p><b><u>Follow-up</u></b> Informational/Advisory</p>
Action	<p>Discussion</p> <ul style="list-style-type: none"> <li>• Operational statistics, including PA and call center metrics up to December 31, 2024, were discussed.</li> <li>• All metrics met or exceeded service level agreements.</li> </ul>	<p><b><u>Conclusion</u></b> The board reviewed and accepted the presentation.</p>

Agenda Item	Discussion	Conclusions/Follow-up
<b>MassHealth Update</b>	<p><b><u>MassHealth Update by Dr. Kimberly Lenz</u></b> MassHealth Update is a summary of recent developments in MassHealth in the context of pharmacy, managed care, or public health.</p>	<p><b><u>Follow-up</u></b> Informational/Advisory</p>

Agenda Item	Discussion	Conclusions/Follow-up
Action	Discussion <ul style="list-style-type: none"> <li>Reviewed current clinical program initiatives</li> <li>Provided direct negotiation status update</li> <li>Discussed operational updates</li> </ul>	<u><b>Conclusion</b></u> The board reviewed and accepted the presentation.

Agenda Item	Discussion	Conclusions/Follow-up
Open Forum	<u><b>Open Forum</b></u>	<u><b>Follow-up</b></u> Informational/Advisory
Action	Discussion <ul style="list-style-type: none"> <li>This presentation was tabled until the next DUR Board meeting.</li> </ul>	<u><b>Conclusion</b></u> N/A

Meeting adjourned at 8:00 p.m.

Respectfully submitted by Mylissa Price

Date: \_\_\_\_\_